Intelligent Bio Solutions Inc. INBS 深 滬
等待開盤 06-25 09:30:00 美东时间
2.20
-0.095
-4.14%
華盛通- 最 高2.3099
- 今 開2.27
- 成交量 6.61万股
- 最 低 2.18
- 昨 收 2.295
- 總市值 526.21万
- 52周最高 24.90
- 市盈率 靜 --
- 換手率 2.76%
- 52周最低 2.18
- 委 比 -50.00%
- 總股本 239.18万
- 歷史最高 34176.00
- 量 比 1.46
- 振 幅 5.66%
- 歷史最低 2.18
- 每 手 1
- 風險率 5.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Intelligent Bio Solutions publishes investor presentation on fingerprint sweat-based rapid drug screening system
Intelligent Bio Solutions publishes investor presentation on fingerprint sweat-based rapid drug screening system Intelligent Bio Solutions highlighted its fingerprint-sweat drug screening system, targeting a 16-24 hour detection window to better indicate potential impairment. System workflow: 5-seco
06-17 12:51
Intelligent Bio Solutions Initiates Multi-Site Method Comparison Study To Support FDA 510(k) Submission For US Market Clearance Of Intelligent Fingerprinting Drug Screening System For Opiate Codeine
Study designed to validate accuracy and real-world workplace performance of the Intelligent Fingerprinting Drug Screening System Company expects to complete enrollment and data collection by the end of July,
06-02 20:36
Intelligent Bio Solutions Q3 EPS $(1.80) Up From $(4.40) YoY, Sales $1.060M Up From $728.867K YoY
Intelligent Bio Solutions (NASDAQ:INBS) reported quarterly losses of $(1.80) per share. This is a 59.09 percent increase over losses of $(4.40) per share from the same period last year. The company reported $1.060
05-13 20:34
Intelligent Bio Solutions Completes Penetration Testing As Part Of Its Upcoming FDA Submission
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of
04-17 20:33
Intelligent Bio Solutions Completes Its Initial Clinical Cut-Off Trial For FDA 510(k) Submission For U.S. Market Clearance Of Its Intelligent Fingerprinting Drug Screening System
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of its
04-02 20:36
Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant
Intelligent Bio Solutions Inc. (INBS) announced the grant of its eighth European patent, EP3752831, which protects advancements in contextualizing fingerprint chemical analysis with fingerprint deposition volume. This innovation enhances the interpretation of substances detected in fingerprint sweat and strengthens the robustness of the testing process, further reinforcing INBS' market position and intellectual property portfolio in Europe. The p...
03-26 12:30
Intelligent Bio Solutions Partners With Bouygues UK For Deployment Of INBS's Fingerprint Drug Screening Technology Across Its UK Operations
Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a partnership with Bouygues UK, a
02-24 21:47
Intelligent Bio Solutions Partners With Bouygues UK for Fingerprint Drug Testing Rollout
Intelligent Bio Solutions Partners With Bouygues UK for Fingerprint Drug Testing Rollout Intelligent Bio Solutions Inc. has partnered with Bouygues UK, a subsidiary of Bouygues Construction, to roll out its fingerprint drug screening technology across Bouygues UK’s operations. The initial deployment
02-24 21:45
Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout
Intelligent Bio Solutions Inc. (INBS) has partnered with Bouygues UK, a subsidiary of Bouygues Construction, to deploy its fingerprint drug testing technology across 13 UK project sites. This collaboration demonstrates the commercial scalability and ROI of INBS's technology, offering a hygienic, efficient, and cost-effective solution compared to third-party services. Bouygues Construction, a global leader with operations in over 50 countries, tra...
02-24 13:45
Intelligent Bio Solutions Q2 EPS $(2.82) Up From $(4.96) YoY, Sales $896.774K Up From $607.494K YoY
Intelligent Bio Solutions (NASDAQ:INBS) reported quarterly losses of $(2.82) per share. This is a 43.15 percent increase over losses of $(4.96) per share from the same period last year. The company reported $896.774
02-12 22:18
